Figure 5 | Laboratory Investigation

Figure 5

From: Vascular endothelial growth factor receptor-3 is a novel target to improve net ultrafiltration in methylglyoxal-induced peritoneal injury

Figure 5

Quantitative PCR analysis of specific mRNA expression in the diaphragm of methylglyoxal mouse models indicated that adenovirus-sVEGFR-3 treatment suppressed lymphangiogenesis as assessed by LYVE-1 and VEGFR-3 mRNA expression; however, there was no difference between the Adeno-sVEGFR-3 and Adeno-LacZ groups in the expression of VEGF-C, -D, CD31, and TGF-β1 mRNA (Day 22). (a) VEGF-C, (b) VEGF-D, (c) LYVE-1, (d) VEGFR-3, (e) CD31, and (f) TGF-β1 mRNA expression in the diaphragms of the indicated mice. (each group, n=6). Lac Z, treatment with Adeno-LacZ; LYVE-1, lymphatic vessel endothelial hyaluronan receptor-1; NS, not significant; R3-Ig, treatment with Adeno-sVEGFR-3-Ig; sVEGFR-3, soluble vascular endothelial growth factor receptor-3; TGF-β, transforming growth factor-beta; VEGFR, vascular endothelial growth factor receptor.

Back to article page